-
公开(公告)号：US09969728B2
公开(公告)日：2018-05-15
申请号：US15038239
申请日：2014-12-08
Applicant: UCB Biopharma SPRL
Inventor： Sabine Defays , Jag Paul Heer , Victoria Elizabeth Jackson , James Andrew Johnson , Boris Kroeplien , John Robert Porter
IPC: C07D471/04 , A61K31/437 , A61K31/4184
CPC classification number: C07D471/04 , A61K31/4184 , A61K31/437 , A61K2300/00
Abstract: A series of substituted 5,6,7,8-tetrahydroimidazo[1,2-α]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09926313B2
公开(公告)日：2018-03-27
申请号：US15101089
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Michael Louis Robert Deligny , Jag Paul Heer , Victoria Elizabeth Jackson , Boris Kroeplien , Fabien Claude Lecomte , John Robert Porter
IPC: C07D471/04 , A61K31/437 , A61K31/506
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506
Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20170081321A1
公开(公告)日：2017-03-23
申请号：US15038766
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D471/04 , A61K31/5377 , A61K31/506 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/5377
Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
![Substituted imidazo[1,2-a]pyrazines as TNF activity modulators](/abs-image/US/2016/10/25/US09475820B2/abs.jpg.150x150.jpg)
公开(公告)号：US09475820B2
公开(公告)日：2016-10-25
申请号：US14414299
申请日：2013-07-05
Applicant: UCB Biopharma SPRL
Inventor： Jonathan Mark Bentley , Daniel Christopher Brookings , Julien Alistair Brown , Thomas Paul Cain , Laura Jane Gleave , Alexander Heifetz , Victoria Elizabeth Jackson , Craig Johnstone , Deborah Leigh , James Madden , John Robert Porter , Matthew Duncan Selby , Zhaoning Zhu
IPC: A61K31/4985 , C07D241/36 , C07D491/107 , C07D487/04 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08
CPC classification number: C07D491/107 , A61K31/4985 , A61K31/506 , A61K31/5377 , A61K31/5513 , C07D451/02 , C07D471/08 , C07D487/04
Abstract: A series of imidazo[1,2-a]pyrazine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. The imidazo[1,2-a]pyrazine derivatives of the disclosure are of general formula
-
5.发明申请公开(公告)号：US20160304514A1
公开(公告)日：2016-10-20
申请号：US15101203
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D471/04 , A61K31/437
CPC classification number: C07D471/04 , A61K31/437
Abstract: A series of substituted 4,5,6,7-tetrahydro-3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，式（I）的一系列取代的4,5,6,7-四氢-3H-咪唑并[4,5-c]吡啶衍生物是人TNFα活性的有效调节剂，因此在治疗和/或 预防各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
Patent Agency Ranking
公开(公告)号：US10093652B2
公开(公告)日：2018-10-09
申请号：US15038287
申请日：2014-12-08
Applicant: UCB Biopharma SPRL
Inventor： Jag Paul Heer , Victoria Elizabeth Jackson , Boris Kroeplien , Fabien Claude Lecomte , John Robert Porter
IPC: A61K35/28 , A01N1/02 , G01N33/569 , C12N5/0789 , C07D401/10 , C07D235/12 , A61K31/4439
Abstract: A series of substituted 4,5,6,7-tetrahydrobenzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09988383B2
公开(公告)日：2018-06-05
申请号：US15100697
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D473/00 , C07D473/32 , A61K31/5377
CPC classification number: C07D473/00 , A61K31/5377 , C07D473/32
Abstract: A series of substituted purine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09932342B2
公开(公告)日：2018-04-03
申请号：US15100690
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Mezher Hussein Ali , Daniel Christopher Brookings , Julien Alistair Brown , Victoria Elizabeth Jackson , Boris Kroeplien , John Robert Porter
IPC: C07D487/04 , A61K31/519 , A61K31/5377
CPC classification number: C07D487/04 , A61K31/519 , A61K31/5377
Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09902720B2
公开(公告)日：2018-02-27
申请号：US15038766
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
IPC: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/5377
CPC classification number: C07D471/04 , A61K31/437 , A61K31/506 , A61K31/5377
Abstract: A series of substituted pyrazolo[1,5-a]pyridine derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US09890174B2
公开(公告)日：2018-02-13
申请号：US15101798
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Julien Alistair Brown , Michael Deligny , Jag Paul Heer , Victoria Elizabeth Jackson , Sophie Jadot , Boris Kroeplien , Malcolm Mac Coss , Yogesh Anil Sabnis , Dominique Louis Léon Swinnen , Nathalie Van Houtvin , Zhaoning Zhu
IPC: C07D491/14 , C07D471/04 , A61K31/437 , A61K31/4375 , C07D491/147 , C07D471/14
CPC classification number: C07D491/147 , C07D471/04 , C07D471/14 , C07D491/14
Abstract: A series of substituted fused tricyclic imidazole derivatives, in particular dihydro-1H-pyrano[4′,3′:4,5]imidazo[1,2-a]pyridine, 1,2,3,4-tetrahydroimidazo[1,2-a:5,4-c′]dipyridine, dihydro-1H-pyrano[3′,4′:4,5]imidazo[1,2-a]pyridine and tetrahydro-6H-cyclohepta[4,5]imidazo[1,2-a]pyridine, and analogs thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
-
-
-
-
-
-
-
-
Search Results
41
records
(took 0.028 seconds)
